Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
Patent Broadly Captures Both High Dose & High Ratio Claims for Future Clinical Doses of PRP Allowed by the Canadian Intellectual Property Office
The proenzymes composition patent is an important part of the IP portfolio covering possible future clinical dosage ranges for PRP, as the Company advances to a Phase 1, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors. The patent has been granted in major jurisdictions such as
“We continue to grow our intellectual property portfolio in key global jurisdictions,” said Mr.
About PRP:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the
To view the Company’s “Mechanism of Action” video on the Company’s lead asset, PRP, please click on the following link: http://www.propanc.com/news-media/video.
About
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the planned studies and market projections described above and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements because of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814093299/en/
Investor Relations and Media Contacts:
irteam@propanc.com
+61-3-9882-0780
Source: